Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody

About the Target

ERBB2 is a target of interest in many antibody-based workflows. The human epidermal growth factor receptor (HER) family drives several human cancers by regulating cell growth, survival, and differentiation through diverse signal transduction pathways. Comprising HER-1, HER-2, HER-3, and HER-4 (ErbB1-4), these receptors feature extracellular ligand binding sites, transmembrane segments, and intracellular domains with tyrosine kinase activity. Depending on the literature source, ERBB2 may also be discussed as Phospho-HER2/ErbB2 (Tyr1221/1222) and Phospho HER2 (Tyr 1221).

Reported cellular context includes cell membrane, cell projection, cytoplasm, and endosome, which can matter when signal is compared across treatments or changing cell states. Following ERBB2 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

ERBB2 is commonly interpreted in the context of cancer and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell membrane, cell projection, and cytoplasm, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cell membrane, cell projection, and cytoplasm across matched conditions
• changes associated with proliferative state, oncogenic signaling, or treatment response
• signal-dependent shifts after ligand, inhibitor, or growth-factor perturbation
• differences between total target abundance and site-specific regulation when modified forms are compared

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for ERBB2. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in ERBB2 reflect biology rather than handling. When interpreting ERBB2, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep ERBB2 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.